Protocol Search - Terminated

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Study Title Status Phase Disease Category Disease Site
GOG-0286BA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial CancerTerminatedII/IIIGynecologic [GY]Uterine Corpus
GOG-0278Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (</= 2 cm) Cervical CancerTerminatedI/IIGynecologic [GY]Cervix
GOG-0264A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary.TerminatedIIGynecologic [GY]Ovarian
NRGF-001Activity Monitoring To Improve Patient Care During Chemoradiotherapy For Locally Advanced Non-small Cell Lung Cancer (La-nsclc)

TerminatedILung [LU]Non-small Cell Lung Cancer
NRG-BN009Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity ≥4 Brain Metastases/Year

TerminatedIIIBrain [BN]Other
GOG-0274 RTOG 1174A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIALTerminatedIIIGynecologic [GY]Cervix
GOG-0279A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the VulvaTerminatedIIGynecologic [GY]Other
GOG-0238A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine CorpusTerminatedIIGynecologic [GY]Uterine Corpus
NRG-GY016A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the OvaryTerminatedIIGynecologic [GY]Ovarian
NRG-HN007An Open Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaTerminatedIIIHead and Neck [HN]Head and Neck
RTOG-0926A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-StagingTerminatedIIGenitourinary [GU]Bladder
RTOG-0539Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk MeningiomasTerminatedIIBrain [BN]Other
RTOG-1010A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal AdenocarcinomaTerminatedIIIGastrointestinal [GI]Esophageal
NRG-BN002Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed GlioblastomaTerminatedIBrain [BN]Malignant Glioma
RTOG-0232A Phase III Study Comparing Combined External Beam Radiation And Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic CarcinomaTerminatedIIIGenitourinary [GU]Prostate
RTOG-0415A Phase III Randomized Study of Hypofractionated 3DCRT/IMRT versus Conventionally Fractionated 3DCRT/IMRT in Patients Treated for Favorable-Risk Prostate CancerTerminatedIIIGenitourinary [GU]Prostate
RTOG-0126A Phase III Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3DCRT/IMRT in Patients Treated for Localized Prostate CancerTerminatedIIIGenitourinary [GU]Prostate
RTOG-1205Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent GlioblastomaTerminatedIIBrain [BN]Other
RTOG-1119Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROGTerminatedIIBreast [BR]Breast
RTOG-1106RTOG 1106/ACRIN 6697, Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedIILung [LU]Non-small Cell Lung Cancer
RTOG-1122Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or GliosarcomaTerminatedIIBrain [BN]Other
NRG-HN003A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)TerminatedIHead and Neck [HN]Head and Neck
RTOG-1114Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System LymphomaTerminatedIIBrain [BN]Other
RTOG-0522A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab C225 [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck CarcinomasTerminatedIIIHead and Neck [HN]Head and Neck
RTOG-9601A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostatectomy for pT3N0 Carcinoma of the ProstateTerminatedIIIGenitourinary [GU]Prostate
RTOG-1203A Randomized Phase III Study Of Standard Vs. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (TIME-C)--RTOG CCOP StudyTerminatedIIIGynecologic [GY]Other
RTOG-0129A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease) for Advanced Head and Neck CarcinomasTerminatedIIIHead and Neck [HN]Head and Neck
RTOG-0938A Randomized Phase II Trial Of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer-RTOG CCOP StudyTerminatedIIGenitourinary [GU]Prostate
RTOG-0813Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable PatientsTerminatedI/IILung [LU]Non-small Cell Lung Cancer
RTOG-0912A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for The Treatment of Anaplastic Thyroid CancerTerminatedIIHead and Neck [HN]Head and Neck
RTOG-0521A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate CancerTerminatedIIIGenitourinary [GU]Prostate
RTOG-0524A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive BladderTerminatedI/IIGenitourinary [GU]Bladder
RTOG-9910A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate CancerTerminatedIIIGenitourinary [GU]Prostate
RTOG-0837Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed GlioblastomaTerminatedIIBrain [BN]Other
RTOG-0617A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung CancerTerminatedIIILung [LU]Non-small Cell Lung Cancer
RTOG-0526A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam RadiotherapyTerminatedIIGenitourinary [GU]Other
RTOG-0712A Phase II Randomized Study for Patients with Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery and Concomitant Chemoradiation by Either BID Irradiation plus 5-Fluorouracil and Cisplatin or QD Irradiation plus Gemcitabine Followed by Selective Bladder Preservation and Gemcitabine/Cisplatin Adjuvant ChemotherapyTerminatedIIGenitourinary [GU]Bladder
RTOG-0424A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade GliomasTerminatedIIBrain [BN]Lower Grade Glioma
RTOG-0913Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed GlioblastomaTerminatedI/IIBrain [BN]Other
RTOG-1014A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBRI) for Local Recurrence of Breast CarcinomaTerminatedIIBreast [BR]Breast
RTOG-0436A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without SurgeryTerminatedIIIGastrointestinal [GI]Esophageal
RTOG-9804Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Ductal Carcinoma In Situ (DCIS) of the Female BreastTerminatedIIIBreast [BR]Breast
NRG-BR001A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple MetastasesTerminatedIBreast [BR]Breast
RTOG-0839Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung CancerTerminatedIILung [LU]Non-small Cell Lung Cancer
GOG-0268A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary.TerminatedIIGynecologic [GY]Ovarian
NRG-GY011A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine CorpusTerminatedIGynecologic [GY]Uterine Corpus
GOG-0210A Molecular Staging Study of Endometrial CarcinomaTerminatedIGynecologic [GY]Uterine Corpus
GOG-0239A Phase II Trial of AZD6244 (NSC #748727, IND #77782) in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or PeritoneumTerminatedIIGynecologic [GY]Ovarian
GOG-0186HA Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin NSC # 729968, BB-IND #13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedIIGynecologic [GY]Ovarian
GOG-0214Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND# 79,610)

TerminatedIIGynecologic [GY]Ovarian
GOG-0199Prospective Study of Risk-Reducing Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
TerminatedIGynecologic [GY]Ovarian
GOG-9923A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab(NSC #704865, IND #7921)and CTEP-Supplied Agent ABT-888(NSC #737664,IND# 77840)in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary PeritCancerTerminatedIGynecologic [GY]Ovarian
RTOG-0631Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine MetastasisTerminatedII/IIISymptom Management [CC]Other
NSABP B-31A Randomized Trial Comparing The Safety And Efficacy Of Adriamycin And Cyclophosphamide Followed By Taxol (AC?T) To That Of Adriamycin And Cyclophosphamide Followed By Taxol Plus Herceptin (AC?T + H) In Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2TerminatedIIIBreast [BR]Breast
NRG-GY008A Phase II Evaluation of Copanlisib BAY 80-6946 IND #130822, A Selective Inhibitor of PI3KCA, in patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot MutationsTerminatedIIGynecologic [GY]Uterine Corpus
NRG-GY002A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical CancerTerminatedIIGynecologic [GY]Cervix
NRG-CC001A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain MetastasesTerminatedIIISymptom Management [CC]Other
GOG-0277A phase III randomized trial of gemcitabine (nsc# 613327) plus docetaxel (nsc#  628503) followed by doxorubicin (nsc# 123127) versus observation for uterus-limited, high-grade uterine leiomyosarcomaTerminatedIIIGynecologic [GY]Uterine Corpus
GOG-0260A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 110072) (NCT# 00888615).TerminatedIIGynecologic [GY]Ovarian
GOG-0186KA Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) versus weekly paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedIIGynecologic [GY]Ovarian
GOG-9926A Phase I Evaluation of Extended Field Radiation Therapy with Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women with Cervical Carcinoma Metastatic to Para-Aortic Lymph NodesTerminatedIGynecologic [GY]Cervix
NRG-GY001A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or PeritoneumTerminatedIIGynecologic [GY]Ovarian
RTOG-0627Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma MultiformeTerminatedIIBrain [BN]Other
NSABP BP-59Bone Marrow Analysis in Early-Stage Breast CancerTerminatedIIIBreast [BR]Breast
NRG-GI001Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic CholangiocarcinomaTerminatedIIIGastrointestinal [GI]Liver
RTOG-1306A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)TerminatedIILung [LU]Non-small Cell Lung Cancer
RTOG-0630A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the ExtremityTerminatedIIOther [DT]Sarcoma
RTOG-9402Phase III Intergroup Randomized Comparison of Radiation Alone Vs Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic OligodendrogliomasTerminatedIIIBrain [BN]Other
RTOG-0621Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II TrialTerminatedIIGenitourinary [GU]Other
RTOG-9408A Phase III Trial of the Study of Endocrine Therapy used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the ProstateTerminatedIIIGenitourinary [GU]Prostate
RTOG-0915A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung CancerTerminatedIILung [LU]Non-small Cell Lung Cancer
RTOG-0618A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung CancerTerminatedIILung [LU]Non-small Cell Lung Cancer
RTOG-0615A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal CancerTerminatedIIHead and Neck [HN]Head and Neck
RTOG-0131A Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic OligoastrocytomasTerminatedIIBrain [BN]CNS Metastatic Disease
RTOG-9813A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)TerminatedI/IIIBrain [BN]Other
RTOG-9802A Phase II Study of Observation in Favorable Low-Grade Glioma and Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade GliomaTerminatedII/IIIBrain [BN]Other
RTOG-0233A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and GemcitabiTerminatedIIGenitourinary [GU]Bladder
GOG-0184A RANDOMIZED PHASE III STUDY OF TUMOR VOLUME DIRECTED PELVIC PLUS OR MINUS PARA-AORTIC IRRADIATION FOLLOWED BY CISPLATIN AND DOXORUBICIN OR CISPLATIN, DOXORUBICIN AND PACLITAXEL FOR ADVANCED ENDOMETRIAL CARCINOMATerminatedIIIGynecologic [GY]Uterine Corpus
GOG-9928A Phase I study of the safety of intraperitoneal EGEN-001 (IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer) administered in combination with pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer patients. The purpose of this studtermine the safety of EGEN-001 IP plus PLD treatment in platinum-recurrent ovarian cancer patients.TerminatedIGynecologic [GY]Ovarian
GOG-9924A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240)in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedIGynecologic [GY]Ovarian
GOG-0280A Phase II Eval of the Poly(ADP-Ribose)Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888)(NSC #737644) in the tx of Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Ca in Patients who carry a germline BRCA 1 or 2 Mutation  TerminatedIIGynecologic [GY]Ovarian
GOG-0207A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, In The Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3TerminatedIIGynecologic [GY]Cervix
RTOG-0537A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced XerostomiaTerminatedII/IIIHead and Neck [HN]Head and Neck
NRG-GY029A Randomized Phase II trial comparing the combination of PI3K inhibitor Copanlisib (BAY 80-6946) and PARP inhibitor Olaparib (AZD2281) to standard chemotherapy in patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer who have progressed through prior PARP inhibitor therapy

Administratively CompleteIIGynecologic [GY]Ovarian
NRG-LU006Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM)TerminatedIIILung [LU]Mesothelioma
NRG-CC004Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo For Sexual Desire in Women With Breast or Gynecologic CancerTerminatedIISymptom Management [CC]Other